DONATE

Strengthening links with Singapore

singaporesmThis week IBEC director Josep Samitier, group leaders Elisabeth Engel, Xavier Trepat and Pere Roca-Cusachs, and Ester Sánchez, representing the Strategic Initiatives Unit, are in Singapore to take part in the first IBEC-MBI Joint Symposium, which took place on 26th September.

The event, hosted by the Mechanobiology Institute (MBI), the National University of Singapore’s dedicated centre focused on exploring this emerging field at the interface of cell biology, physics, engineering and computational biology, aimed to foster collaboration between the two institutions.

The programme included sessions on specific fields of research shared by the two centers, namely cell-matrix interactions, regenerative medicine, matrix to nucleus transduction, collective cell migration, and featured speakers from both sides.

“El futuro en 3D”

elfutureYesterday, La Sexta broadcast the documentary “El futuro en 3D” about the different options offered by 3D printing.

New strategies to combat malaria: heparin and nanomedicine

The Institute for Bioengineering of Catalonia (IBEC), the Barcelona Institute for Global Health (ISGlobal) and the biotech firm Bioiberica have signed a partnership agreement to study the development of new compounds derived from heparin to combat malaria.

The partnership, which was officially announced this morning at the BioSpain meeting in Bilbao, is based on the research undertaken by Dr Xavier Fernández-Busquets, head of IBEC and ISGlobal’s joint Nanomalaria unit, engaged in developing specific antimalaria therapies, and the R&D project of Bioiberica, world leader in heparin production, to seek new applications of this molecule.

Every year malaria infects 200 million people worldwide and causes half a million deaths. For several decades it has been known that when the malaria parasite enters the bloodstream, it invades the liver cells to produce thousands of merozoites – a stage in the life cycle of the parasite – that enter into the circulation and infect red blood cells, managing to evade the immune system.

“Alianza contra el cáncer”

2016-09-15_ferreribecThe recent news about the new consortium comprising pharmaceutical company Ferrer, IBEC and the bioinformatics company Mind the Byte to study the development of new therapeutic molecules against cancer metastasis was covered in several national newspapers.

IBEC’s participation at B·Debate

Xavier Rubies, head of IBEC’s Technology Transfer unit, took part in last week’s B · Debate conference on “Fighting Blindness. Future Opportunities and Challenges for Visual Restoration”, organized by the Barcelona Macula Foundation in collaboration with the Centre for Genomic Regulation (CRG) and LEITAT.

IBEC's participation at B·Debate

Xavier took part in the “From Bench to Bedside” round table, where he explained the process of bringing research results to market. The other speakers agreed with his position that in order to achieve effective results, it’s necessary to start by looking at demand, and then to lead the transfer of projects according to the needs of the market.

This B · Debate conference, an initiative of Biocat and Obra Social “la Caixa”, aimed to explore the potential of new therapeutic approaches for retinal dystrophies, combining nanotechnology, regenerative medicine, stem cells, gene therapy, genomics, bioengineering, photonics and optogenetics.

Call for Predoctoral Candidates to Apply for 2017 FI-Gencat Grants


Application Deadline: 22/09/2016 before 17:00h (Spanish time)
Ref: (please check each Research Group reference code)
 
The Institute for Bioengineering of Catalonia (IBEC) is looking for Predoctoral candidates to apply for the 2017 call from the Generalitat of Catalonia (FI-2017).